Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma

a multicenter retrospective analysis

Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, Won Seog Kim, Seok Jin Kim, Jae Cheol Jo, Jinseok Kim, Won Sik Lee, Sung Yong Oh, Yong Park, Sung Yong Kim, Mark Hong Lee, Ho Sup Lee, Young Rok Do

Research output: Contribution to journalArticle

Abstract

Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea. Patients received an intravenous (IV) infusion of rituximab at a dose of 375 mg/m2 on day 1. On days 2 and 3, patients received an IV infusion of bendamustine at doses of 120 or 90 mg/m2. Median age was 69 (range 18–86), 74.1% had stage III or IV disease, and 67.2% showed high-intermediate or high International Prognostic Index scores at diagnosis. In an intention-to-treat analysis, 18 patients (31.0%) showed a complete response and 14 (24.1%) showed a partial response, resulting in an overall response rate of 55.1%. The median duration of the response was 3.7 months (range 1.0–47.2 months). The median progression-free survival was 3.9 months (95% confidence interval [CI], 2.4–5.4 months), and the median overall survival was 6.7 months (95% CI, 4.7–8.7 months). The most common grade 3/4 adverse event was neutropenia (n = 40; 68.9%). Febrile neutropenia was observed in 11 patients (18.9%). Grade 3/4 thrombocytopenia was observed in 34 patients (58.6%). Our study confirmed the high efficacy and acceptable toxicity profile of BR in relapsed or refractory DLBCL patients. However, we need to closely observe the higher tendency of grade 3/4 hematological toxicities in Korean patients.

Original languageEnglish
Pages (from-to)1437-1443
Number of pages7
JournalAnnals of Hematology
Volume97
Issue number8
DOIs
Publication statusPublished - 2018 Aug 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Intravenous Infusions
Confidence Intervals
Mantle-Cell Lymphoma
Febrile Neutropenia
Intention to Treat Analysis
Rituximab
Bendamustine Hydrochloride
Stem Cell Transplantation
Korea
Neutropenia
Tertiary Care Centers
Disease-Free Survival
Lymphoma
Safety
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Hong, Jung Yong ; Yoon, Dok Hyun ; Suh, Cheolwon ; Kim, Won Seog ; Kim, Seok Jin ; Jo, Jae Cheol ; Kim, Jinseok ; Lee, Won Sik ; Oh, Sung Yong ; Park, Yong ; Kim, Sung Yong ; Lee, Mark Hong ; Lee, Ho Sup ; Do, Young Rok. / Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma : a multicenter retrospective analysis. In: Annals of Hematology. 2018 ; Vol. 97, No. 8. pp. 1437-1443.
@article{6cec000298794b5e8249ba9bd96179e5,
title = "Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis",
abstract = "Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea. Patients received an intravenous (IV) infusion of rituximab at a dose of 375 mg/m2 on day 1. On days 2 and 3, patients received an IV infusion of bendamustine at doses of 120 or 90 mg/m2. Median age was 69 (range 18–86), 74.1{\%} had stage III or IV disease, and 67.2{\%} showed high-intermediate or high International Prognostic Index scores at diagnosis. In an intention-to-treat analysis, 18 patients (31.0{\%}) showed a complete response and 14 (24.1{\%}) showed a partial response, resulting in an overall response rate of 55.1{\%}. The median duration of the response was 3.7 months (range 1.0–47.2 months). The median progression-free survival was 3.9 months (95{\%} confidence interval [CI], 2.4–5.4 months), and the median overall survival was 6.7 months (95{\%} CI, 4.7–8.7 months). The most common grade 3/4 adverse event was neutropenia (n = 40; 68.9{\%}). Febrile neutropenia was observed in 11 patients (18.9{\%}). Grade 3/4 thrombocytopenia was observed in 34 patients (58.6{\%}). Our study confirmed the high efficacy and acceptable toxicity profile of BR in relapsed or refractory DLBCL patients. However, we need to closely observe the higher tendency of grade 3/4 hematological toxicities in Korean patients.",
author = "Hong, {Jung Yong} and Yoon, {Dok Hyun} and Cheolwon Suh and Kim, {Won Seog} and Kim, {Seok Jin} and Jo, {Jae Cheol} and Jinseok Kim and Lee, {Won Sik} and Oh, {Sung Yong} and Yong Park and Kim, {Sung Yong} and Lee, {Mark Hong} and Lee, {Ho Sup} and Do, {Young Rok}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s00277-018-3317-6",
language = "English",
volume = "97",
pages = "1437--1443",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "8",

}

Hong, JY, Yoon, DH, Suh, C, Kim, WS, Kim, SJ, Jo, JC, Kim, J, Lee, WS, Oh, SY, Park, Y, Kim, SY, Lee, MH, Lee, HS & Do, YR 2018, 'Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis', Annals of Hematology, vol. 97, no. 8, pp. 1437-1443. https://doi.org/10.1007/s00277-018-3317-6

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma : a multicenter retrospective analysis. / Hong, Jung Yong; Yoon, Dok Hyun; Suh, Cheolwon; Kim, Won Seog; Kim, Seok Jin; Jo, Jae Cheol; Kim, Jinseok; Lee, Won Sik; Oh, Sung Yong; Park, Yong; Kim, Sung Yong; Lee, Mark Hong; Lee, Ho Sup; Do, Young Rok.

In: Annals of Hematology, Vol. 97, No. 8, 01.08.2018, p. 1437-1443.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma

T2 - a multicenter retrospective analysis

AU - Hong, Jung Yong

AU - Yoon, Dok Hyun

AU - Suh, Cheolwon

AU - Kim, Won Seog

AU - Kim, Seok Jin

AU - Jo, Jae Cheol

AU - Kim, Jinseok

AU - Lee, Won Sik

AU - Oh, Sung Yong

AU - Park, Yong

AU - Kim, Sung Yong

AU - Lee, Mark Hong

AU - Lee, Ho Sup

AU - Do, Young Rok

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea. Patients received an intravenous (IV) infusion of rituximab at a dose of 375 mg/m2 on day 1. On days 2 and 3, patients received an IV infusion of bendamustine at doses of 120 or 90 mg/m2. Median age was 69 (range 18–86), 74.1% had stage III or IV disease, and 67.2% showed high-intermediate or high International Prognostic Index scores at diagnosis. In an intention-to-treat analysis, 18 patients (31.0%) showed a complete response and 14 (24.1%) showed a partial response, resulting in an overall response rate of 55.1%. The median duration of the response was 3.7 months (range 1.0–47.2 months). The median progression-free survival was 3.9 months (95% confidence interval [CI], 2.4–5.4 months), and the median overall survival was 6.7 months (95% CI, 4.7–8.7 months). The most common grade 3/4 adverse event was neutropenia (n = 40; 68.9%). Febrile neutropenia was observed in 11 patients (18.9%). Grade 3/4 thrombocytopenia was observed in 34 patients (58.6%). Our study confirmed the high efficacy and acceptable toxicity profile of BR in relapsed or refractory DLBCL patients. However, we need to closely observe the higher tendency of grade 3/4 hematological toxicities in Korean patients.

AB - Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea. Patients received an intravenous (IV) infusion of rituximab at a dose of 375 mg/m2 on day 1. On days 2 and 3, patients received an IV infusion of bendamustine at doses of 120 or 90 mg/m2. Median age was 69 (range 18–86), 74.1% had stage III or IV disease, and 67.2% showed high-intermediate or high International Prognostic Index scores at diagnosis. In an intention-to-treat analysis, 18 patients (31.0%) showed a complete response and 14 (24.1%) showed a partial response, resulting in an overall response rate of 55.1%. The median duration of the response was 3.7 months (range 1.0–47.2 months). The median progression-free survival was 3.9 months (95% confidence interval [CI], 2.4–5.4 months), and the median overall survival was 6.7 months (95% CI, 4.7–8.7 months). The most common grade 3/4 adverse event was neutropenia (n = 40; 68.9%). Febrile neutropenia was observed in 11 patients (18.9%). Grade 3/4 thrombocytopenia was observed in 34 patients (58.6%). Our study confirmed the high efficacy and acceptable toxicity profile of BR in relapsed or refractory DLBCL patients. However, we need to closely observe the higher tendency of grade 3/4 hematological toxicities in Korean patients.

UR - http://www.scopus.com/inward/record.url?scp=85044935258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044935258&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3317-6

DO - 10.1007/s00277-018-3317-6

M3 - Article

VL - 97

SP - 1437

EP - 1443

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 8

ER -